Faricimab + Ranibizumab + Sham Procedure
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Neovascularization, Choroidal
Conditions
Neovascularization, Choroidal, Macular Degeneration, Age-Related
Trial Timeline
Jan 27, 2017 → Mar 29, 2018
NCT ID
NCT03038880About Faricimab + Ranibizumab + Sham Procedure
Faricimab + Ranibizumab + Sham Procedure is a phase 2 stage product being developed by Roche for Neovascularization, Choroidal. The current trial status is completed. This product is registered under clinical trial identifier NCT03038880. Target conditions include Neovascularization, Choroidal, Macular Degeneration, Age-Related.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03038880 | Phase 2 | Completed |
| NCT02484690 | Phase 2 | Completed |
Competing Products
16 competing products in Neovascularization, Choroidal
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| ranibizumab | Novartis | Approved | 85 |
| Ranibizumab | Novartis | Approved | 85 |
| Ranibizumab 0.5mg + Ranibizumab 0.5 mg + Verteporfin PDT | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| ranibizumab | Novartis | Phase 3 | 77 |
| Intravitreal injection ranibizumab | Novartis | Phase 2 | 52 |
| Ranibizumab | Novartis | Phase 3 | 77 |
| Ranibizumab | Novartis | Phase 1/2 | 41 |
| Faricimab + Ranibizumab | Roche | Phase 3 | 77 |
| Faricimab + Ranibizumab + Sham Procedure | Roche | Phase 2 | 52 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Regeneron Pharmaceuticals | Pre-clinical | 22 |
| Subconjunctival aflibercept | Regeneron Pharmaceuticals | Phase 1 | 32 |
| Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321) | Bayer | Pre-clinical | 20 |
| Aflibercept (Eylea, BAY86-5321) | Bayer | Pre-clinical | 20 |
| 4D-150 IVT (3E10 vg/eye) + EYLEA® (aflibercept) Injection 2 mg (0.05mL) | 4D Molecular Therapeutics | Phase 3 | 69 |